(Q33894486)

29 July 2017

title

Imaging growth and isocitrate dehydrogenase 1 mutation are independent predictors for diffuse low-grade gliomas (English)

1 reference

29 July 2017

11

0 references

Pascale Varlet

object named as

Pascale Varlet

7

0 references

author name string

Catherine Gozé

1

1 reference

29 July 2017

Marie Blonski

2

1 reference

29 July 2017

Guillaume Le Maistre

3

1 reference

29 July 2017

Luc Bauchet

4

1 reference

29 July 2017

Edouard Dezamis

5

1 reference

29 July 2017

Philippe Page

6

1 reference

29 July 2017

Laurent Capelle

8

1 reference

29 July 2017

Bertrand Devaux

9

1 reference

29 July 2017

Luc Taillandier

10

1 reference

29 July 2017

Johan Pallud

12

1 reference

29 July 2017

publication date

20 May 2014

1 reference

29 July 2017

1 reference

29 July 2017

volume

16

1 reference

29 July 2017

issue

8

1 reference

29 July 2017

page(s)

1100-1109

1 reference

IDH/MGMT-driven molecular classification of low-grade glioma is a strong predictor for long-term survival

29 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4096178

Velocity of tumor spontaneous expansion predicts long-term outcomes for diffuse low-grade gliomas

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4096178

Expression of R132H mutational IDH1 in human U87 glioblastoma cells affects the SREBP1a pathway and induces cellular proliferation

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4096178

Mutant IDH1 is required for IDH1 mutated tumor cell growth.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4096178

Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4096178

Quantitative morphological magnetic resonance imaging follow-up of low-grade glioma: a plea for systematic measurement of growth rates

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4096178

Dynamic imaging response following radiation therapy predicts long-term outcomes for diffuse low-grade gliomas

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4096178

Mutations in CIC and FUBP1 contribute to human oligodendroglioma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4096178

Predictive and prognostic factors for gliomas

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4096178

IDH1 R132H decreases proliferation of glioma cell lines in vitro and in vivo

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4096178

Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4096178

IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4096178

Preoperative prognostic classification system for hemispheric low-grade gliomas in adults

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4096178

Prognostic significance of imaging contrast enhancement for WHO grade II gliomas

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4096178

Computational modeling of the WHO grade II glioma dynamics: principles and applications to management paradigm

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4096178

Pretreatment factors predict overall survival for patients with low-grade glioma: a recursive partitioning analysis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4096178

Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task Force.

5 July 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOU085

Prognostic factors for survival in adult patients with cerebral low-grade glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOU085

IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOU085

Prognostic value of initial magnetic resonance imaging growth rates for World Health Organization grade II gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOU085

Continuous growth of mean tumor diameter in a subset of grade II gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOU085

All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOU085

Dynamic history of low-grade gliomas before and after temozolomide treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOU085

1P19Q loss but not IDH1 mutations influences WHO grade II gliomas spontaneous growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOU085

Neoadjuvant chemotherapy may optimize the extent of resection of World Health Organization grade II gliomas: a case series of 17 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOU085

Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOU085

Prognostic significance of IDH mutation in adult low-grade gliomas: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOU085

A population-based study of low-grade gliomas and mutated isocitrate dehydrogenase 1 (IDH1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOU085

No prognostic value of IDH1 mutations in a series of 100 WHO grade II astrocytomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOU085

IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-free survival and prolonged postrecurrence survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOU085

TERT promoter mutations rather than methylation are the main mechanism for TERT upregulation in adult gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOU085

Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOU085

The effect of extent of resection on recurrence in patients with low grade cerebral hemisphere gliomas

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24847087

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1093/NEUONC/NOU085

1 reference

29 July 2017

1 reference

29 July 2017

1 reference